t
Accrol Group Holdings plc announced the appointment of Shore Capital Stockbrokers as a Joint Broker, effective March 7, 2023. Shore Capital Stockbrokers will work alongside Zeus, the Company's existing Nominated Adviser and Joint Broker.
| Date | 7 Mar 2023 |
| Time | 07:00:06 |
| Category | Corporate updates |
| ID | 0581S |
7 March 2023
Accrol Group Holdings plc
("Accrol", the "Group" or the "Company")
APPOINTMENT OF JOINT BROKER
Accrol Group, the UK's leading independent tissue converter, is pleased to announce the appointment of Shore Capital Stockbrokers as Joint Broker, to work alongside Zeus, the Company's Nominated Adviser and Joint Broker, with immediate effect.
|
For further information, please contact: |
|
|
|
|
|
Accrol Group Holdings plc |
|
|
Dan Wright, Executive Chairman |
Via Belvedere Communications |
|
Gareth Jenkins, Chief Executive Officer Richard Newman, Chief Financial Officer |
|
|
|
|
|
Zeus (Nominated Adviser & Joint Broker) |
|
|
Dan Bate / Jordan Warburton |
Tel: +44 (0) 161 831 1512 |
|
Dominic King |
Tel: +44 (0) 203 829 5000 |
|
|
|
|
Shore Capital Stockbrokers (Joint Broker) |
Tel: +44 (0) 20 7408 4090 |
|
Malachy McEntyre / Mark Percy / James Thomas |
|
|
|
|
|
Belvedere Communications Limited |
|
|
Cat Valentine |
Tel: +44 (0) 7715 769 078 |
|
Keeley Clarke |
Tel: +44 (0) 7967 816 525 |
|
|
Overview of Accrol
Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK. The Group now operates from six manufacturing sites, including four in Lancashire, which together supply c.21.5% (volume) of the UK tissue market valued at c£2.5bn at retail sales value.
For more information, please visit www.accrol.com.